Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Thrombosis and Thrombolysis
Published in: Journal of Thrombosis and Thrombolysis 3/2022

01-04-2022 | Disseminated Intravascular Coagulation

A comprehensive review of vascular complications in COVID-19

Authors: Yogesh Acharya, Aqeel Alameer, Gavin Calpin, Maha Alkhattab, Sherif Sultan

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2022

Login to get access

Abstract

This study aims to review the available literature pertinent to vascular complications in COVID-19. A systematic search was performed using PubMed and Google Scholar to identify all relevant studies based on our study objective. Multiple studies have reported widespread systemic inflammation and procoagulant/hypercoagulable state in COVID-19, including thrombotic microangiopathy, endothelial dysfunction, bleeding disorder, and thrombosis. However, large specialised studies on vascular complications are lacking despite current evidence indicating dysfunctional coagulation pathways. Furthermore, there are no clear and definitive recommendations regarding thromboprophylaxis or full therapeutic anticoagulation in COVID-19. Several studies have reported hypercoagulability and vascular complications as important predictors of patient outcome in COVID-19. Therefore, it is important to understand the pathogenesis, epidemiology, management, and outcomes of patients who develop venous or arterial thrombosis and those with a pre-existing thrombotic disease who contract COVID-19 for risk stratification, thromboprophylaxis, optimal antithrombotic therapy during active infection and long-term anticoagulation following discharge or recovery.
Literature
1.
2.
Liu PP, Blet A, Smyth D et al (2020) The science underlying COVID-19: implications for the cardiovascular system. Circulation 142:68–78PubMedCrossRef
3.
Oudkerk M, Büller HR, Kuijpers D et al (2020) Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology 297:E216–E222PubMedCrossRef
4.
Guan WJ, Ni ZY, Hu Y et al (2020) China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720PubMedCrossRef
5.
Tang N, Li D, Wang X et al (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847PubMedPubMedCentralCrossRef
6.
Wang D, Hu B, Hu C et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China [published correction appears in JAMA. 2021 Mar 16;325(11):1113]. JAMA 2020;323:1061-1069
7.
Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30;:]. Lancet 2020;395:497-506
8.
Zhang Y, Cao W, Xiao M et al (2020) [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi 41:E006PubMed
9.
Ranucci M, Ballotta A, Di Dedda U et al (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18:1747–1751PubMedCrossRef
10.
Zou Y, Guo H, Zhang Y et al (2020) Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China. Biosci Trends 14:285–289PubMedCrossRef
11.
Zhang T, Sun LX, Feng RE (2020) [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019]. Zhonghua Jie He He Hu Xi Za Zhi 43:496–502PubMed
12.
13.
Menter T, Haslbauer JD, Nienhold R et al (2020) Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. Histopathology 77:198–209PubMedPubMedCentralCrossRef
14.
Jenkins PV, O’Donnell JS (2006) ABO blood group determines plasma von Willebrand factor levels: a biologic function after all? Transfusion 46:1836–1844PubMedCrossRef
15.
Franchini M, Mannucci PM (2014) ABO blood group and thrombotic vascular disease. Thromb Haemost 112:1103–1109PubMedCrossRef
16.
Guillon P, Clement M, Sebille V et al (2008) Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti‐histo‐blood group antibodies. Glycobiology 18:1085–1093PubMedCrossRef
17.
Lax SF, Skok K, Zechner P et al (2020) Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 173:350–361PubMedCrossRef
18.
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054–1062PubMedPubMedCentralCrossRef
19.
Fogarty H, Townsend L, Ni Cheallaigh C et al (2020) COVID19 coagulopathy in Caucasian patients. Br J Haematol 189:1044–1049PubMedCrossRef
20.
Yang X, Yang Q, Wang Y et al (2020) Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 18:1469–1472PubMedCrossRef
21.
Yin S, Huang M, Li D et al (2021) Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J Thromb Thrombolysis 51:1107–1110PubMedCrossRef
22.
Hughes C, Nichols T, Pike M et al (2020) Cerebral venous sinus thrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med 7:001691PubMedPubMedCentral
23.
24.
Rech TH, Girardi AM, Gazzana MB (2020) Incidence of pulmonary embolism in patients with COVID-19. Intensive Care Med 46:1500–1501PubMedCrossRef
25.
Helms J, Tacquard C, Severac F et al, CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis) (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46:1089–1098PubMedPubMedCentralCrossRef
26.
Middeldorp S, Coppens M, van Haaps TF et al (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 18:1995–2002PubMedPubMedCentralCrossRef
27.
Hippensteel JA, Burnham EL, Jolley SE (2020) Prevalence of venous thromboembolism in critically ill patients with COVID-19. Br J Haematol 190:e134–e137PubMedCrossRef
28.
Léonard-Lorant I, Delabranche X, Séverac F et al (2020) Acute pulmonary embolism in patients with COVID-19 at CT angiography and relationship to d-Dimer levels. Radiology 296:E189–E191PubMedCrossRef
29.
Poissy J, Goutay J, Caplan M et al (2020) Lille ICU haemostasis COVID-19 group. Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence. Circulation 142:184–186PubMedCrossRef
30.
Langer F, Kluge S, Klamroth R et al (2020) Coagulopathy in COVID-19 and its implication for safe and efficacious thromboprophylaxis. Hamostaseologie 40:264–269PubMedPubMedCentralCrossRef
31.
Oxley TJ, Mocco J, Majidi S et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382:e60PubMedCrossRef
32.
Al-Samkari H, Karp Leaf RS, Dzik WH et al (2020) COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136:489–500PubMedCrossRef
33.
Fraissé M, Logre E, Pajot O et al (2020) Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study. Crit Care 24:275PubMedPubMedCentralCrossRef
34.
Koumoutsea EV, Vivanti AJ, Shehata N et al (2020) COVID-19 and acute coagulopathy in pregnancy. J Thromb Haemost 18:1648–1652CrossRef
35.
36.
Khalil A, von Dadelszen P, Draycott T et al (2020) Change in the incidence of stillbirth and preterm delivery during the COVID-19 pandemic. JAMA 324:705–706PubMedCentralCrossRef
37.
Homer CSE, Leisher SH, Aggarwal N et al (2021) Counting stillbirths and COVID 19-there has never been a more urgent time. Lancet Glob Health 9:e10–e11PubMedCrossRef
38.
Lee PY, Day-Lewis M, Henderson LA et al (2020) Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. J Clin Invest 130:5942–5950PubMedPubMedCentralCrossRef
39.
Dufort EM, Koumans EH, Chow EJ et al (2020) New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med 383:347–358CrossRefPubMed
40.
Bhatta S, Sayed A, Ranabhat B et al. New-Onset Seizure as the Only Presentation in a Child With COVID-19. Cureus 2020;12:e8820
41.
Moraleda C, Serna-Pascual M, Soriano-Arandes A, EPICO-AEP Working Group et al (2021) Multi-inflammatory syndrome in children related to severe acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain. Clin Infect Dis 72:e397–e401PubMedCrossRef
42.
43.
Harenberg J, Favaloro E (2020) COVID-19: progression of disease and intravascular coagulation - present status and future perspectives. Clin Chem Lab Med 58:1029–1036PubMedCrossRef
44.
Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood 135:2033–2040PubMedCrossRef
45.
Di Micco P, Russo V, Carannante N et al (2020) Clotting factors in COVID-19: epidemiological association and prognostic values in different clinical presentations in an Italian Cohort. J Clin Med 9:1371PubMedCentralCrossRef
46.
Iba T, Levy JH, Levi M et al (2020) Coagulopathy of coronavirus disease 2019. Crit Care Med 48:1358–1364PubMedCrossRef
47.
Bowles L, Platton S, Yartey N et al (2020) Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med 383:288–290PubMedCrossRef
48.
Zhang Y, Xiao M, Zhang S et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382:e38PubMedCrossRef
49.
50.
Bikdeli B, Madhavan MV, Jimenez D et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2950-2973
51.
Klok FA, Kruip MJHA, van der Meer NJM et al (2020) Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res 191:148–150PubMedPubMedCentralCrossRef
52.
Llitjos JF, Leclerc M, Chochois C et al (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 18:1743–1746PubMedCrossRef
53.
Watson RA, Johnson DM, Dharia RN et al (2020) Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system. Hosp Pract (1995) 48:169–179CrossRef
54.
Kollias A, Kyriakoulis KG, Dimakakos E et al (2020) Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action. Br J Haematol 189:846–847PubMedCrossRef
55.
Beccara A, Pacioni L, Ponton C, Francavilla S, Cuzzoli S (2020) Arterial mesenteric thrombosis as a complication of SARS-CoV-2 infection. Eur J Case Rep Intern Med 7:001690
56.
57.
Barrett CD, Moore HB, Yaffe MB et al (2020) ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A comment. J Thromb Haemost 18:2060–2063PubMedCrossRef
58.
Murphy DA, Hockings LE, Andrews RK et al (2015) Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev 29:90–101PubMedCrossRef
59.
Beyls C, Huette P, Abou-Arab O et al (2020) Extracorporeal membrane oxygenation for COVID-19-associated severe acute respiratory distress syndrome and risk of thrombosis. Br J Anaesth 8:1121–1131
60.
Barbaro RP, MacLaren G, Boonstra PS et al. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry [published correction appears in Lancet. 2020 Oct 10;396(10257):1070]. Lancet 2020;396:1071-1078
61.
Guo Z, Sun L, Li B et al (2021) Anticoagulation management in severe coronavirus disease 2019 patients on extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth 35:389–397PubMedCrossRef
62.
Shekar K, Badulak J, Peek G et al (2020) Extracorporeal life support organization coronavirus disease 2019 interim guidelines: a consensus document from an International group of interdisciplinary extracorporeal membrane oxygenation providers. ASAIO J 66:707–721PubMedCrossRef
63.
Rivosecchi RM, Arakelians AR, Ryan J et al (2021) Comparison of Anticoagulation Strategies in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation: Heparin Versus Bivalirudin. Crit Care Med 49:1129–1136PubMed
64.
Parzy G, Daviet F, Puech B et al (2020) Venous Thromboembolism Events Following Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Syndrome Coronavirus 2 Based on CT Scans. Crit Care Med 48:e971–e975PubMedCrossRef
65.
Jones C, Chen K, Narendran VC, Series (2021) The Coexistence of Thrombocytopenia and Thromboembolism in COVID-19 Patients on ECMO: A Case Series and Literature Review. Front Med (Lausanne) 8:731352CrossRef
66.
Steinlechner B, Kargl G, Schlömmer C et al (2021) Can Heparin-Coated ECMO Cannulas Induce Thrombocytopenia in COVID-19 Patients? Case Reports Immunol 2021:6624682PubMedPubMedCentralCrossRef
67.
Doyle AJ, Hunt BJ, Sanderson B et al (2021) A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation. Crit Care Med 49:e663–e672PubMed
68.
69.
Deng Y, Liu W, Liu K et al (2020) Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl) 133:1261–1267CrossRef
70.
Wright FL, Vogler TO, Moore EE et al (2020) Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J Am Coll Surg 231:193-203.e1PubMedPubMedCentralCrossRef
71.
Cui S, Chen S, Li X et al (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 18:1421–1424PubMedCrossRef
72.
Poggiali E, Bastoni D, Ioannilli E et al (2020) Deep vein thrombosis and pulmonary embolism: two complications of COVID-19 Pneumonia? Eur J Case Rep Intern Med 7:001646PubMedPubMedCentral
73.
Grillet F, Behr J, Calame P et al (2020) Acute pulmonary embolism associated with COVID-19 Pneumonia detected with pulmonary CT angiography. Radiology 296:E186–E188PubMedCrossRef
74.
75.
Liu J, Li S, Liu J et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763PubMedPubMedCentralCrossRef
76.
Joly BS, Siguret V, Veyradier A (2020) Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19. Intensive Care Med 46:1603–1606PubMedCrossRef
77.
Thachil J, Agarwal S (2020) Understanding the COVID-19 coagulopathy spectrum. Anaesthesia 75:1432–1436PubMedCrossRef
78.
Gavriilaki E, Brodsky RA, Severe (2020) COVID-19 infection and thrombotic microangiopathy: success does not come easily. Br J Haematol 189:e227–e230PubMedCrossRef
79.
Diurno F, Numis FG, Porta G (2020) al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24:4040–4047PubMed
80.
Thomas W, Varley J, Johnston A et al (2020) Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom. Thromb Res 191:76–77PubMedPubMedCentralCrossRef
Metadata
Title
A comprehensive review of vascular complications in COVID-19
Authors
Yogesh Acharya
Aqeel Alameer
Gavin Calpin
Maha Alkhattab
Sherif Sultan
Publication date
01-04-2022
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2022
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02593-2

Other articles of this Issue 3/2022

Journal of Thrombosis and Thrombolysis 3/2022 Go to the issue

OriginalPaper

Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality

OriginalPaper

Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes

OriginalPaper

Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic

OriginalPaper

COVID-19 risk index (CRI): a simple and validated emergency department risk score that predicts mortality and the need for mechanical ventilation

Report

Delayed diagnosis of congenital thrombotic thrombocytopenic purpura in a patient with recurrent strokes

OriginalPaper

Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits